Pharmaceutical Technology

SEPTEMBER 9, 2022

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). Gatehouse Bio is engaged in developing small RNA-based therapeutics using AI technology.

RNA 246

RNA Development Gene Therapy Gene 246

Pharmaceutical Technology

AUGUST 3, 2023

AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.

RNA 244

RNA Vaccination Vaccine Development 244

Bio Pharma Dive

SEPTEMBER 6, 2022

A handful of startups have formed in recent years with plans to target RNA with small molecules. Many have caught the attention of big drugmakers.

RNA 291

RNA Drugs 291

Bio Pharma Dive

AUGUST 30, 2021

Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus.

RNA 349

RNA 349

Bio Pharma Dive

AUGUST 23, 2022

At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand.

RNA 329

RNA Medicine Drugs 329

Pharmaceutical Technology

MAY 23, 2023

ReNAgade Therapeutics has burst onto the RNA technology scene by announcing a $300m financing round. With its delivery system, Cambridge, Massachusetts-based biotech says it aims to “address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body.”

RNA 147

RNA Gene Editing Gene Vaccination 147

Bio Pharma Dive

JULY 25, 2022

The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.

RNA 246

RNA Licensing Licensing Drugs 246

Bio Pharma Dive

SEPTEMBER 5, 2023

The biotech, one of several advancing RNA editing medicines, expects to obtain “proof-of-mechanism” data in patients with the inherited disorder alpha-1 antitrypsin deficiency by next year.

RNA 174

RNA Medicine 174

Pharmaceutical Technology

APRIL 22, 2024

Discover how Silence Therapeutics' patented compound for RNA interference therapy targets liver disease with precision. Learn about the specific chemical formula and potential therapeutic benefits outlined in the recently granted patent.

RNA 130

RNA 130

Bio Pharma Dive

NOVEMBER 9, 2021

The biotech is researching how to make medicines from transfer RNA molecules. Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.

RNA 359

RNA Medicine Drugs Research 359

Bio Pharma Dive

JANUARY 3, 2024

The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.

RNA 174

RNA Drugs Development 174

Bio Pharma Dive

OCTOBER 12, 2022

The startup, run by Translate Bio cofounder Romesh Subramanian, believes its RNA “exon editing” approach could have long-lasting effects without the risks that come with editing DNA.

RNA 257

RNA DNA 257

Pharmaceutical Technology

JUNE 1, 2023

A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. It will focus on studying and developing new lipid nanoparticle (LNP) formulations for the delivery of RNA medicine.

Drug Delivery 242

Drug Delivery RNA Development Drugs 242

BioSpace

DECEMBER 3, 2023

From the skin to the lungs to the central nervous system, biotech companies are making progress toward delivering RNA therapeutics to multiple targets throughout the body. But challenges remain.

RNA 140

RNA 140

Bio Pharma Dive

MAY 10, 2021

Laronde comes equipped with $50 million in funding from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines.

RNA 350

RNA Medicine 350

Bio Pharma Dive

SEPTEMBER 7, 2022

“We see a huge opportunity in the setting of RNA-based therapies to overcome some of the shortcomings that have been there with the first generation of RNA companies,” said former Alnylam CEO and Orbital Therapeutics co-founder John Maraganore.

RNA 229

RNA Drugs 229

Pharmaceutical Technology

MARCH 1, 2023

Further, the acceptance of new mRNA vaccines has rejuvenated activity within previously established categories of RNA therapeutics including lifesaving antisense technologies. These include antisense oligonucleotides (ASO), RNA interference (RNAi), and RNA aptamers.

RNA 147

RNA Vaccination Vaccine Genetics 147

Bio Pharma Dive

JANUARY 11, 2022

Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more.

RNA 257

RNA Drugs Development 257

Bio Pharma Dive

JULY 6, 2021

The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs.

RNA 297

RNA Drugs Medicine 297

Pharmaceutical Technology

JUNE 16, 2023

from Flanders Innovation & Entrepreneurship (VLAIO) to further advance its oncology portfolio targeting RNA. It will also support the firm’s preclinical effort on the long non-coding RNA (LncRNA) programme, FTX-001, that targets MALAT-1. Flamingo Therapeutics has received a research grant of €1.7m

RNA 173

RNA Gene Therapy Gene Clinical Trials 173

Pharmaceutical Technology

DECEMBER 13, 2023

Daiichi Sankyo plans to leverage the French startup’s technology to develop its RNA-targeted therapeutics pipeline.

RNA 147

RNA Drugs Development 147

pharmaphorum

MARCH 25, 2024

billion, adding expertise in RNA therapeutics and a heart failure therapy in mid-stage trials. Novo Nordisk has agreed to buy Cardior Pharmaceuticals for $1.1

RNA 122

RNA Trials 122

BioSpace

APRIL 21, 2024

Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.

RNA 127

RNA Development Drugs Research 127

Pharmaceutical Technology

APRIL 27, 2023

Orbital Therapeutics has raised $270m in a Series A round led by ARCH Venture Partners to advance a portfolio of programmable RNA therapeutics. Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement.

RNA 130

RNA Medicine Gene Therapy Gene 130

Bio Pharma Dive

MAY 23, 2023

Staffed by many former Alnylam and Moderna employees, the startup is developing technologies that could be useful in a variety of RNA drugmaking methods.

RNA 186

RNA Drugs Development 186

pharmaphorum

APRIL 22, 2024

bn alliance with Skyhawk Therapeutics focused on RNA-modulating drugs for rare neurological diseases. Ipsen agrees $1.8

RNA 110

RNA Drugs 110

Pharmaceutical Technology

NOVEMBER 13, 2023

Heqet Therapeutics and Ethris have collaborated to develop RNA-based therapeutics to treat cardiovascular conditions.

RNA 130

RNA Development 130

Pharma Times

APRIL 29, 2024

The method has the potential to be used to deliver RNA to the bloodstream for a range of diseases

RNA 120

RNA Drugs 120

Bio Pharma Dive

SEPTEMBER 8, 2021

The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen.

RNA 271

RNA Medicine Research 271

BioSpace

OCTOBER 15, 2023

The next frontier in RNA therapies, RNA editing has the potential to treat both genetic and common disorders, and the technology is rapidly expanding beyond the liver.

RNA 120

RNA Genetics 120

Pharmaceutical Technology

NOVEMBER 2, 2023

While things may have slowed down a little since the rapid approvals of the COVID-19 vaccines, the excitement around RNA-LNP is still going strong.

RNA 130

RNA Manufacturing Vaccination Vaccine 130

Bio Pharma Dive

FEBRUARY 17, 2022

The agreement with the Cambridge-based startup is the latest to reflect growing large pharma company interest in targeting RNA with small molecules.

RNA 192

RNA Pharma Companies Research 192

BioSpace

OCTOBER 8, 2023

Its reversible nature offers the potential for RNA editing to go beyond rare diseases, eliciting excitement and buy-in from large pharmas like GSK and Eli Lilly.

RNA 128

RNA 128

Pharmaceutical Technology

OCTOBER 11, 2022

Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. It also intends to turn the insights from its research into RNA-based drug candidates, and they will be tested in human livers at the company’s recently opened ‘Liver ICUs’ in the US.

RNA 130

RNA Development Genome Genomics 130

pharmaphorum

NOVEMBER 29, 2023

Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower dose.

RNA 115

RNA Regulation Vaccination Vaccine 115

AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 1, 2023

The Drug Controller General of India (DCGI) has added in-vitro diagnostic (IVD) medical devices including those for diagnosis of Covid-19, ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) extraction kits, among others into the Class C risk category under the Medical Devices Rules (MDR), 2017.

RNA 163

RNA DNA In-Vitro Drugs 163

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

RNA 345

RNA Vaccination Vaccine Trials 345